Oral Ketamine Therapy Shows Promise in Rare Mutism Case

A Single Case Report Describes Remission After Oral Ketamine Therapy

A case report published in the peer-reviewed journal Cureus describes a patient with recurrent dissociative neurological symptom disorder involving mutism who reached prolonged remission after a course of oral ketamine-assisted psychotherapy, according to the report's title as indexed on Google News on October 13, 2026. Dissociative neurological symptom disorder, also called functional neurological disorder, is a condition in which a person experiences real neurological symptoms, such as loss of speech, paralysis, or seizure-like episodes, that are not explained by structural disease and are instead linked to how the brain processes stress, trauma, or emotional conflict. Mutism in this context means the patient periodically lost the ability to speak despite having no physical damage to the vocal tract or speech centers.

Oral ketamine-assisted psychotherapy, often abbreviated KAP, pairs a low, sub-anesthetic oral dose of ketamine with structured talk therapy sessions, on the premise that the drug's temporary dissociative and mood-altering effects can help patients access and process difficult material they otherwise avoid. The full text of this specific report was not available for this summary, so details such as exact dosing, number of sessions, and length of follow-up are not confirmed here and would need to be checked against the published paper for anyone evaluating the claim closely.

Why One Case Report Isn't Proof of a Treatment Pattern

Case reports sit at the bottom of the medical evidence hierarchy for a reason: they describe what happened to one person, under one set of circumstances, without comparison to patients who received a different treatment or no treatment at all. Functional neurological disorder is also known to have a notably high rate of spontaneous or placebo-linked improvement, and dissociative symptoms in particular can respond strongly to the ritual, attention, and expectation built into any structured therapy, independent of the specific drug used. That means a reported remission following oral ketamine-assisted psychotherapy could reflect the ketamine, the psychotherapy, the therapeutic relationship, natural fluctuation in the disorder, or some combination, and a single case cannot separate those factors.

It's also worth noting that oral ketamine-assisted psychotherapy for dissociative neurological symptom disorder is not an FDA-approved indication. Ketamine itself is FDA-approved only as an anesthetic agent, while esketamine (Spravato) is approved specifically for treatment-resistant depression and depression with suicidal ideation, administered under supervision in certified settings. Any use for functional neurological disorder, mutism, or general psychotherapy support falls outside those approvals and is considered off-label, meaning a licensed prescriber is using clinical judgment to apply a drug approved for one purpose to a different condition. Off-label use is legal and common in medicine, but it means the evidence base is thinner and insurance coverage is less predictable.

What This Means for Patients Considering Ketamine Therapy

For readers living with functional neurological disorder, dissociative episodes, or related mutism, a report like this one is worth knowing about but shouldn't drive a treatment decision on its own. The practical path is to raise it with a neurologist and a psychiatrist or therapist who already understand your diagnosis, and ask specifically how a single case report fits against the broader, still-limited research on ketamine for dissociative and trauma-related conditions. Functional neurological disorder is typically managed first with specialized physical therapy, cognitive behavioral therapy, and in some cases antidepressant or anti-anxiety medication; ketamine-assisted psychotherapy would be an add-on or alternative approach rather than a frontline treatment at this point.

If you're evaluating a ketamine clinic or ketamine-assisted psychotherapy provider for any dissociative or trauma-related diagnosis, ask direct questions: what is the clinic's experience treating functional neurological disorder specifically, who provides the psychotherapy component and what are their credentials, how is the oral dose determined and monitored, and what is the plan if symptoms return after the drug's effects wear off. Oral ketamine has different absorption and bioavailability than the intravenous or intranasal forms used in most depression research, so dosing experience matters and shouldn't be assumed to transfer directly from IV protocols.

The original case report is referenced via Google News at the Cureus journal listing, and readers who want the full clinical details, including exact dosing, session structure, and length of remission, should request the full text through a medical library or the journal directly before drawing firm conclusions. Case reports like this one are a starting point for larger studies, not a substitute for them, and patients should expect it will take controlled trials, likely years away, before oral ketamine-assisted psychotherapy for dissociative neurological symptom disorder has a settled evidence base.